Matamec Explorations Announces Study Details from Kipawa Deposit

Matamec Explorations Inc. (TSX VENTURE:MAT) announces a comparative study by Wu et al. from the Institute of Geology and Geophysics of the Chinese Academy of Sciences, Beijing, China, published in volume 273, May 2010 edition, of Chemical Geology.

The study details the chemical composition of eudialyte from 9 alkaline syenites from the following locales:

  • Kipawa (Quebec)
  • Mont St-Hilaire (Quebec)
  • Khibiny (Russia)
  • Lovozero (Russia)
  • Illimaussaq (Greenland)
  • Saima (China)
  • Tamazeght (Marocco)
  • Poços das Caldas (Brazil)
  • Langesund Fjord (Norway)

Wu et al. conclude that eudialyte from the Kipawa deposit has a unique composition characterized by:

- The highest overall value of heavy rare earths (La to Gd)

- The lowest ratio of light rare earths (La to Gd) to heavy rare earths (Tb to Lu

This independent study was carried out using the latest in high precision analysis methods (laser ablation coupled with a high resolution mass spectrometer).

André Gauthier, President of Matamec, comments that: "This is yet another brick in the mounting wall of evidence underlining the quality and unique heavy rare earth enrichment of the eudialyte found at the Kipawa deposit. It also demonstrates the foresight of companies like Unocal/Molycorp who targeted Kipawa eudialyte in the mid '80s as an yttrium source that could potentially compete with the low production costs of the South China Clays."

Aline Leclerc, geologist (OGQ) and Vice-President Exploration of Matamec, is the qualified person for this press release. As qualified person, she has supervised the preparation of the scientific and technical information for the Zeus property and verified the data in this press release.

Source: Matamec Explorations Inc.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.